BACKGROUND

Neurodegenerative diseases arise from a progressive loss of structure and function of neurons leading to conditions including Parkinson’s, Alzheimer’s, Huntington’s, and multiple sclerosis. Most patients use L-DOPA for treatment which can lead to long-term motor complications. In addition, most of the currently available therapeutics can only reduce the symptoms and there is a need for a complete remedy.

The present invention relates to a method of managing neurodegenerative by administering an effective amount of a compound (tyrosine kinase inhibitor or sirtuin-2 inhibitor or a combination thereof) capable of inhibiting or modulating inflammation in the subject. It mainly inhibits neuroinflammation in neurons surrounding cells.

 

APPLICATIONS

  • Effective compound for managing the neuroinflammation-mediated neurodegenerative disease.

  • It can be used for Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple sclerosis, and amyotrophic lateral sclerosis.

 

ADVANTAGES

  • The composition is formulated into dosage form selected from groups comprising a solid oral formulation, liquid formulation, and parenteral formulation or any combinations thereof.

  • Controlled as well as prolonged-release formulations are contemplated.


Commercialization

A PCT application has been filed bearing application number PCT/IB2017/053362.